Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

elanco animal health inc. - ELAN

ELAN

Close Chg Chg %
13.43 0.10 0.71%

Open Market

13.53

+0.10 (0.71%)

Volume: 3.06M

Last Updated:

Nov 21, 2024, 1:35 PM EDT

Trade Now

Company Overview: elanco animal health inc. - ELAN

ELAN Key Data

Open

$13.37

 Day Range

13.26 - 13.53

52 Week Range

11.40 - 18.77

 Market Cap

$6.64B

Shares Outstanding

494.35M

 Public Float

487.53M

Beta

1.42

 Rev. Per Employee

N/A

P/E Ratio

32.89

 EPS

$0.41

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

4.42M

  

ELAN Performance

1 Week
 
 -3.86%
 
1 Month
 
 8.30%
 
3 Months
 
 -7.76%
 
1 Year
 
 12.56%
 
5 Years
 
 -49.83%
 

ELAN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About elanco animal health inc. - ELAN

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

ELAN At a Glance

Elanco Animal Health, Inc.
2500 Innovation Way
Greenfield, Indiana 46140
Phone 1-877-352-6261 Revenue 4.42B
Industry Biotechnology Net Income -1,231,000,000.00
Sector Health Technology 2023 Sales Growth 0.136%
Fiscal Year-end 12 / 2024 Employees 9,800
View SEC Filings

ELAN Valuation

P/E Current 32.893
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.661
Price to Book Ratio 1.18
Price to Cash Flow Ratio 27.067
Enterprise Value to EBITDA 12.646
Enterprise Value to Sales 2.92
Total Debt to Enterprise Value 0.459

ELAN Efficiency

Revenue/Employee 450,714.286
Income Per Employee -125,612.245
Receivables Turnover 3.811
Total Asset Turnover 0.296

ELAN Liquidity

Current Ratio 2.745
Quick Ratio 1.347
Cash Ratio 0.284

ELAN Profitability

Gross Margin 43.876
Operating Margin 7.381
Pretax Margin -27.055
Net Margin -27.87
Return on Assets -8.247
Return on Equity -18.221
Return on Total Capital -10.141
Return on Invested Capital -9.881

ELAN Capital Structure

Total Debt to Total Equity 95.067
Total Debt to Total Capital 48.735
Total Debt to Total Assets 41.192
Long-Term Debt to Equity 93.942
Long-Term Debt to Total Capital 48.159
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Elanco Animal Health Inc. - ELAN

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
3.27B 4.76B 4.41B 4.42B
Sales Growth
+6.59% +45.57% -7.43% +0.14%
Cost of Goods Sold (COGS) incl D&A
2.03B 2.69B 2.44B 2.48B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
516.90M 716.00M 682.00M 694.00M
Depreciation
157.00M 160.00M 89.00M 92.00M
Amortization of Intangibles
359.90M 556.00M 593.00M 602.00M
COGS Growth
+21.30% +32.74% -9.26% +1.56%
Gross Income
1.25B 2.08B 1.97B 1.94B
Gross Income Growth
-10.96% +66.43% -5.06% -1.62%
Gross Profit Margin
+38.09% +43.55% +44.66% +43.88%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.32B 1.77B 1.59B 1.61B
Research & Development
327.00M 369.00M 321.00M 327.00M
Other SG&A
996.60M 1.40B 1.26B 1.28B
SGA Growth
+28.47% +33.95% -10.55% +1.64%
Other Operating Expense
- - - -
-
Unusual Expense
625.30M 673.00M 188.00M 1.16B
EBIT after Unusual Expense
(702.10M) (371.00M) 196.00M (836.00M)
Non Operating Income/Expense
186.10M 68.00M (12.00M) (82.00M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
156.00M 264.00M 256.00M 277.00M
Interest Expense Growth
+97.72% +69.23% -3.03% +8.20%
Gross Interest Expense
156.00M 264.00M 256.00M 277.00M
Interest Capitalized
- - - -
-
Pretax Income
(672.00M) (567.00M) (72.00M) (1.20B)
Pretax Income Growth
-959.34% +15.63% +87.30% -1,559.72%
Pretax Margin
-20.53% -11.90% -1.63% -27.05%
Income Tax
(111.90M) (95.00M) 6.00M 36.00M
Income Tax - Current - Domestic
(42.70M) 1.00M 12.00M (6.00M)
Income Tax - Current - Foreign
55.60M 58.00M 51.00M 122.00M
Income Tax - Deferred - Domestic
(100.00K) (10.00M) (21.00M) (14.00M)
Income Tax - Deferred - Foreign
(124.70M) (144.00M) (36.00M) (66.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(560.10M) (472.00M) (78.00M) (1.23B)
Minority Interest Expense
- - - -
-
Net Income
(560.10M) (472.00M) (78.00M) (1.23B)
Net Income Growth
-924.89% +15.73% +83.47% -1,478.21%
Net Margin Growth
-17.11% -9.91% -1.77% -27.87%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(560.10M) (472.00M) (78.00M) (1.23B)
Preferred Dividends
- - - -
-
Net Income Available to Common
(560.10M) (472.00M) (78.00M) (1.23B)
EPS (Basic)
-1.2689 -0.9688 -0.1597 -2.5005
EPS (Basic) Growth
-789.62% +23.65% +83.52% -1,465.75%
Basic Shares Outstanding
441.40M 487.20M 488.30M 492.30M
EPS (Diluted)
-1.2689 -0.9688 -0.1597 -2.5005
EPS (Diluted) Growth
-791.88% +23.65% +83.52% -1,465.75%
Diluted Shares Outstanding
441.40M 487.20M 488.30M 492.30M
EBITDA
440.10M 1.02B 1.07B 1.02B
EBITDA Growth
-35.70% +131.31% +4.72% -4.32%
EBITDA Margin
+13.45% +21.36% +24.17% +23.09%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 18.70
Number of Ratings 14 Current Quarters Estimate 0.154
FY Report Date 12 / 2024 Current Year's Estimate 0.92
Last Quarter’s Earnings 0.13 Median PE on CY Estimate N/A
Year Ago Earnings 0.89 Next Fiscal Year Estimate 0.925
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 9 13 13
Mean Estimate 0.15 0.31 0.92 0.93
High Estimates 0.17 0.34 0.95 1.05
Low Estimate 0.14 0.25 0.91 0.83
Coefficient of Variance 6.07 9.26 1.43 6.07

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 2 2 1
HOLD 5 5 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Elanco Animal Health Inc. - ELAN

Date Name Shares Transaction Value
Aug 14, 2024 Jeffrey N. Simmons PRESIDENT, CEO AND DIRECTOR; Director 145,000 Open market or private purchase of non-derivative security Non-derivative transaction at $13.01 per share 1,886,450.00
Jul 17, 2024 Rajeev Modi SEE REMARKS 1,252 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Lawrence Erik Kurzius Director 29,528 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 William F. Doyle Director 76,330 Open market or private purchase of non-derivative security Non-derivative transaction at $16.98 per share 1,296,083.40
Apr 8, 2024 Tim Bettington SEE REMARKS 106,387 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.43 per share 1,641,551.41
Mar 21, 2024 Todd S. Young SEE REMARKS 95,749 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2024 Todd S. Young SEE REMARKS 138,176 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.03 per share 2,214,961.28
Mar 21, 2024 Todd S. Young SEE REMARKS 152,176 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2024 Todd S. Young SEE REMARKS 100,177 Bona fide gift 0.00
Mar 21, 2024 Todd S. Young SEE REMARKS 149,308 Bona fide gift 0.00
Mar 21, 2024 Todd S. Young SEE REMARKS 152,308 Bona fide gift 0.00
Mar 21, 2024 Todd S. Young SEE REMARKS 150,808 Bona fide gift 0.00
Mar 21, 2024 Todd S. Young SEE REMARKS 3,500 Bona fide gift 0.00
Mar 21, 2024 Todd S. Young SEE REMARKS 3,500 Bona fide gift 0.00
Mar 13, 2024 Michael J. Harrington Director 77,594 Open market or private purchase of non-derivative security Non-derivative transaction at $16.29 per share 1,264,006.26
Mar 11, 2024 R. David Hoover Director 185,000 Open market or private purchase of non-derivative security Non-derivative transaction at $16.14 per share 2,985,900.00
Mar 6, 2024 Jeffrey N. Simmons PRESIDENT, CEO AND DIRECTOR; Director 1,367,467 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.03 per share 21,920,496.01
Mar 6, 2024 Jeffrey N. Simmons PRESIDENT, CEO AND DIRECTOR; Director 408,164 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Ellen de Brabander SEE REMARKS 124,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Ellen de Brabander SEE REMARKS 114,886 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.03 per share 1,841,622.58

Elanco Animal Health Inc. in the News